OpenSecrets reports the pharma industry led lobbying in Q2 2025, spending $105.4 million, followed by Ballard Partners at $20 ...

Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks ...

Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America - the industry's ...

This piece is the first in a series exploring the foundational players in the U.S. healthcare system: payers, providers, ...

President Trump has imposed a 15 percent tariff on most items in a trade agreement with the European Union, with ...

And pharmaceutical companies spend big on lobbying in Washington — more than any other industry in 2017 — helping to assure victories like the 2003 Medicare Part D legislation which banned the ...

The threat comes as Trump's administration pressures pharmaceutical companies to lower drug prices for Americans.

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...

ZEYNEP TUFEKCI: The pharmaceutical industry heads into Musk's wood chipper Wednesday, Feb. 12, 2025 -- The National Institutes of Health would slash funding for medical research doesn't make even ...

BNP Secretary General Mirza Fakhrul Islam Alamgir has warned of a severe crisis in the pharmaceutical industry, alleging that ...

The pharmaceutical sector, a beacon of innovation, stands tall in Europe's economic landscape. Yet even a robust industry is not immune to financial challenges.

Let's see why the pharmaceutical industry is now in need of innovation more than ever, how it can navigate through the hype around AI and harness value and how long that might take.